NIH launches 2 monoclonal antibody trials for COVID-19
The NIH will launch two clinical trials, one each for inpatients and outpatients, as part of its Accelerating COVID-19 Therapeutic Intervention and Vaccines program to test the safety and efficacy of Eli Lilly's monoclonal antibody LY-CoV555 as a potential treatment for patients in the early stages of a COVID-19 infection. NBC News (8/4)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!